Clinical trial · Observational
PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer
PET-MR Fusion Imaging and Surrogate Marker for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is: To validate the efficacy of multiparametric MRI, FDG-PET, RGD-PET, and PET-MR fusion imaging in the prediction and monitoring response to neoadjuvant chemotherapy of locally advanced breast cancer patients. To identify the optimal combination parameters of MR spectroscopy, diffusion-weighted MRI, dynamic contrast-enhanced MRI, FDG-PET, and RGD-PET in the prediction and monitoring response to neoadjuvant chemotherapy of locally advanced breast cancer patients. To compare the performances of dynamic contrast-enhanced MRI using parametric response map analysis versus those of pharmacokinetic parameters (Ktrans, kep, or Ve) in the early prediction of pathological responsiveness to neoadjuvant chemotherapy in breast cancer patients
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Patholocial Response to Chemotherapy
- timeFrame
- Post-operation
- description
- Pathological complete response (pCR) or non-pCR
Secondary outcomes (8)
- measure
- Tumor Size
- timeFrame
- baseline, completion of 1st cycle of chemotherapy
- description
- Maximal tumor diameter measured on magnetic resonance imaging
- measure
- Tumor Volume
- timeFrame
- Baseline, post-1st chemotherapy
- description
- Tumor volume measured on 3-dimensional magnetic resonance imaging
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed breast cancer * Clinical stage IIb, IIIa, IIIb, IIIc * Must have measurable disease * Performance status of ECOG 0-2 * Adequate, bone marrow, liver, heart, and renal function * Who did not receive chemotherapy for breast cancer * Must agree with and signed informed consent Exclusion Criteria: * Prior history of cancer besides breast cancer * Active bacterial infection * Pregnant or lactating women * Psychological disease or seizure * History of arrhythmia, congestive heart failure, myocardial infarct, or unstable angina * Male breast cancer * Who had a pacemaker or history of open heart surgery
References
Publications (1)
- DERIVEDCho N, Im SA, Park IA, Lee KH, Li M, Han W, Noh DY, Moon WK. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging. Radiology. 2014 Aug;272(2):385-96. doi: 10.1148/radiol.14131332. Epub 2014 Apr 13. PMID 24738612